Ribosomes moved nearly twice as fast on ac4C-modified mRNA in human and mouse cells, producing more therapeutic protein than the current standard. The work proposes ribosome collisions as a cause of lower output on m1Ψ. doi.org/hcgcrs
Alternative mRNA modification lets ribosomes move nearly twice as fast
In a new study, scientists from Johns Hopkins Medicine report that an experimental mRNA-based platform has the potential to help deliver next-generation mRNA therapeutics, including vaccines to fight infectious diseases, cancer and autoimmune conditions, faster and more efficiently than the industry standard.
phys.org